NCT04613271View on ClinicalTrials.gov

Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia

PHASE3CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

October 15, 2020

Primary Completion Date

October 25, 2021

Study Completion Date

November 8, 2021

Conditions
Infectious DiseaseSARS-CoV InfectionCovid19
Interventions
DRUG

Favipiravir

"Assignment of Administration Group 1:~Favipiravir 1600 mg twice a day at day 1 and 600 mg twice a day at day 7-14 + Azithromycin 500 mg once a day for 5 days."

DRUG

Azithromycin

Azithromycin 500 mg once a day for 5 days.

Trial Locations (3)

14340

RSPI Sulianti Saroso, Jakarta

50244

RSUP Dr. Kariadi, Semarang

56115

RSJ Soerodjo, Magelang

All Listed Sponsors
collaborator

Center for Research and Development of Health Resources and Services, National Institute of Health Research and Development (NIHRD), Indonesia

UNKNOWN

lead

Ina-Respond

OTHER

NCT04613271 - Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia | Biotech Hunter | Biotech Hunter